Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis

被引：0
|
作者：
Soon, Yu Yang
Marschner, Ian
Hofman, Michael S.
Emmett, Louise
Davis, Ian D.
Stockler, Martin R.
Martin, Andrew James
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[2] Natl Univ Canc Inst, Dept Radiat Oncol, Singapore, Singapore
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[5] St Vincents Hosp, Sydney, NSW, Australia
[6] Monash Univ, Box Hill, Vic, Australia
[7] Eastern Hlth, Box Hill, Vic, Australia
[8] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5045
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry
    Burgard, Caroline
    Hein, Connor
    Blickle, Arne
    Bartholomae, Mark
    Maus, Stephan
    Petto, Sven
    Schaefer-Schuler, Andrea
    Ezziddin, Samer
    Rosar, Florian
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (03) : 885 - 895
  • [42] Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands
    Heynickx, Nathalie
    Segers, Charlotte
    Coolkens, Amelie
    Baatout, Sarah
    Vermeulen, Koen
    PHARMACEUTICALS, 2023, 16 (05)
  • [43] Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
    Rosar, Florian
    Schon, Niklas
    Bohnenberger, Hendrik
    Bartholoma, Mark
    Stemler, Tobias
    Maus, Stephan
    Khreish, Fadi
    Ezziddin, Samer
    Schaefer-Schuler, Andrea
    EJNMMI PHYSICS, 2021, 8 (01)
  • [44] A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
    Jia, Angela Y.
    Spratt, Daniel
    LANCET ONCOLOGY, 2024, 25 (10): : 1246 - 1247
  • [45] Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
    Rosar, Florian
    Kochems, Niklas
    Bartholomae, Mark
    Maus, Stephan
    Stemler, Tobias
    Linxweiler, Johannes
    Khreish, Fadi
    Ezziddin, Samer
    CANCERS, 2021, 13 (12)
  • [46] Re-challenge [177Lu]Lu-PSMA-617 in patients with advanced prostate cancer: outcome and safety
    Yordanova, Anna
    Essler, Markus
    Hauser, Stefan
    Feldmann, Georg
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [47] Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [177Lu]Lu-PSMA-617 in Healthy Organs
    Mueller, Marco
    Lucaroni, Laura
    Favalli, Nicholas
    Bassi, Gabriele
    Neri, Dario
    Cazzamalli, Samuele
    Oehler, Sebastian
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (10) : 8247 - 8260
  • [48] [177Lu]Lu-PSMA-617 (Pluvicto™): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
    Hennrich, Ute
    Eder, Matthias
    PHARMACEUTICALS, 2022, 15 (10)
  • [49] Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?
    Sartor, Oliver
    LANCET ONCOLOGY, 2022, 23 (11): : 1344 - 1345
  • [50] Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
    Florian Rosar
    Niklas Schön
    Hendrik Bohnenberger
    Mark Bartholomä
    Tobias Stemler
    Stephan Maus
    Fadi Khreish
    Samer Ezziddin
    Andrea Schaefer-Schuler
    EJNMMI Physics, 8
12345